New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: Case report and review

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 2, 1999, Pages 161-164

  Lee, Elmer C C ^a   Walmsley, Sharon ^a   Fantus, I George ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMETABOLITE; BRONCHODILATING AGENT; HORMONE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIARRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MALE; RASH;

EID: 0033609434     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
2. Maurer M. Megestrol for AIDS-related anorexia. Ann Intern Med 1995; 122:880.
3. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinning M. Glucocorticoid like activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature [review]. Arch Intern Med 1997;157(15):1651-6.
4. Kontula K, Paravonen T, Luukkainen T, Anderson LC. Binding of progestins to the glucocorticoid receptor. Biochem Pharmacol 1983;32:1511-8.
5. Ault A. FDA warns of potential protease-inhibitor link to hyperglycemia [news]. Lancet 1997;349:1819.
6. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycemia [letter]. Lancet 1997;350:713-4.
7. Nightingale SL. From the Food and Drug Administration. JAMA 1997; 278(5):379.
8. Visnegarmalx F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
9. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997;127:948.
10. Diabetes, protease-inhibitor link improved: directorate [news]. CMAJ 1997; 157(5):502-3.
11. Dever LL, Oruwari PA, O'Donovan CA, Eng RHK. Hyperglycemia associated with protease-inhibitors in HIV-infected patients. Proceedings of the 37th Interscience Conference on Antimicrobial. Agents and Chemotherapy [1997 Sept 28-Oct 1; Toronto]. Washington: American Society for Microbiology; 1997. Abstract LB-09.
12. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68
13. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-15.
14. DeFronzo R, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic vascular disease. Diabetes Care 1991;14:173-84.
15. Porte D. Beta cells in type II diabetes mellitus. Diabetes 1991;40:166-80.
16. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, et al. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1996;333:1386-90.
17. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
18. Cawley NX, Pu LP, Loh YT. Immunological identification and localization of yeast aspartic protease 3-like prohormone-processing enzymes in mammalian brain and pituitary. Endocrinology 1996;137:5135-43.
19. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
20. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hypherlipidaemia and insulin resistance in patients receiving in HIV protease inhibitors. AIDS 1998;12:F51-F58.
21. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 1998;351:1881-3.
22. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
23. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70.
24. Hirano Y, Mitamura T, Tamura T, Ohara K, Mine Y, Noguchi H. Mechanism of FK506-induced glucose intolerance in rats. J Toxicol Sci 1994;19:61-5.
25. Bouchard P, Sai P, Reach G, Caubarrere I, Geneval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in Humans. Diabetes 1982;31:40-5.
26. Albrecht H, Stellbrink HJ, Arasteh K. Didanosine-induced disorders of glucose tolerance. Ann Intern Med 1993;119:1050.
27. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-39.